Glp-1 Derivatives And Uses Thereof


Ontology type: sgo:Patent     


Patent Info

DATE

N/A

AUTHORS

KOFOED, JACOB , KODRA, János, Tibor , LINDEROTH, LARS , GARIBAY, PATRICK, WILLIAM

ABSTRACT

The invention relates to GLP-1 analogues and derivatives having a Trp at a position corresponding to position 8 of GLP-1(7-37), and their pharmaceutical use e.g. in the treatment of type 2 diabetes. These Trp8 compounds are very stable against degradation by DPP-IV, while maintaining the capability to bind to and activate the GLP-1 receptor. The derivatives have one or two substituents (P-L) attached to a Lys residue of the GLP-1 analogue via an optional Branching group (B), wherein P is a Protracting moiety such as a fatty diacid, and L is a linker consisting of one or more linker elements such as, for example, 8-amino-3,6-dioxaoctanoic acid. Examples of compounds of the invention include the 8W variants of liraglutide and dulaglutide. The invention also relates to a method for the fully recombinant preparation of 8W GLP-1 analogues and derivatives which is more simple and thereby cheaper as compared to the preparation of known GLP-1 analogues that have been DPP-IV stabilised by inclusion of one or more non-coded amino acids. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2464", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "KOFOED, JACOB", 
        "type": "Person"
      }, 
      {
        "name": "KODRA, J\u00e1nos, Tibor", 
        "type": "Person"
      }, 
      {
        "name": "LINDEROTH, LARS", 
        "type": "Person"
      }, 
      {
        "name": "GARIBAY, PATRICK, WILLIAM", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250050903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013633156", 
          "https://doi.org/10.1007/s001250050903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250050903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013633156", 
          "https://doi.org/10.1007/s001250050903"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0022-2836(70)90057-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021169618"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1039/b312953p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052479461"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "description": "

The invention relates to GLP-1 analogues and derivatives having a Trp at a position corresponding to position 8 of GLP-1(7-37), and their pharmaceutical use e.g. in the treatment of type 2 diabetes. These Trp8 compounds are very stable against degradation by DPP-IV, while maintaining the capability to bind to and activate the GLP-1 receptor. The derivatives have one or two substituents (P-L) attached to a Lys residue of the GLP-1 analogue via an optional Branching group (B), wherein P is a Protracting moiety such as a fatty diacid, and L is a linker consisting of one or more linker elements such as, for example, 8-amino-3,6-dioxaoctanoic acid. Examples of compounds of the invention include the 8W variants of liraglutide and dulaglutide. The invention also relates to a method for the fully recombinant preparation of 8W GLP-1 analogues and derivatives which is more simple and thereby cheaper as compared to the preparation of known GLP-1 analogues that have been DPP-IV stabilised by inclusion of one or more non-coded amino acids.

", "id": "sg:patent.WO-2017149070-A1", "keywords": [ "derivative", "invention", "GLP-1 analog", "TRP", "Glucagon-Like Peptide 1", "pharmaceutical use", "type 2 diabetes", "compound", "degradation", "DPP IV", "capability", "GLP-1 receptor", "substituents", "PS", "Lys residue", "branching", "wherein", "moiety", "linker", "element", "amino", "variant", "liraglutide", "method", "preparation", "analog", "inclusion", "amino acid" ], "name": "GLP-1 DERIVATIVES AND USES THEREOF", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.425956.9", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/WO-2017149070-A1" ], "sdDataset": "patents", "sdDatePublished": "2019-03-07T15:34", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com.uberresearch.data.dev.patents-pipeline/full_run_10/sn-export/5eb3e5a348d7f117b22cc85fb0b02730/0000100128-0000348334/json_export_962f20a5.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.WO-2017149070-A1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.WO-2017149070-A1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.WO-2017149070-A1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.WO-2017149070-A1'


 

This table displays all metadata directly associated to this object as RDF triples.

71 TRIPLES      14 PREDICATES      44 URIs      35 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.WO-2017149070-A1 schema:about anzsrc-for:2464
2 schema:author N057739cbb3a540efb087ed1e3d52bf45
3 schema:citation sg:pub.10.1007/s001250050903
4 https://doi.org/10.1016/0022-2836(70)90057-4
5 https://doi.org/10.1039/b312953p
6 schema:description <p num="0000">The invention relates to GLP-1 analogues and derivatives having a Trp at a position corresponding to position 8 of GLP-1(7-37), and their pharmaceutical use e.g. in the treatment of type 2 diabetes. These Trp8 compounds are very stable against degradation by DPP-IV, while maintaining the capability to bind to and activate the GLP-1 receptor. The derivatives have one or two substituents (P-L) attached to a Lys residue of the GLP-1 analogue via an optional Branching group (B), wherein P is a Protracting moiety such as a fatty diacid, and L is a linker consisting of one or more linker elements such as, for example, 8-amino-3,6-dioxaoctanoic acid. Examples of compounds of the invention include the 8W variants of liraglutide and dulaglutide. The invention also relates to a method for the fully recombinant preparation of 8W GLP-1 analogues and derivatives which is more simple and thereby cheaper as compared to the preparation of known GLP-1 analogues that have been DPP-IV stabilised by inclusion of one or more non-coded amino acids.</p>
7 schema:keywords DPP IV
8 GLP-1 analog
9 GLP-1 receptor
10 Glucagon-Like Peptide 1
11 Lys residue
12 PS
13 TRP
14 amino
15 amino acid
16 analog
17 branching
18 capability
19 compound
20 degradation
21 derivative
22 element
23 inclusion
24 invention
25 linker
26 liraglutide
27 method
28 moiety
29 pharmaceutical use
30 preparation
31 substituents
32 type 2 diabetes
33 variant
34 wherein
35 schema:name GLP-1 DERIVATIVES AND USES THEREOF
36 schema:recipient https://www.grid.ac/institutes/grid.425956.9
37 schema:sameAs https://app.dimensions.ai/details/patent/WO-2017149070-A1
38 schema:sdDatePublished 2019-03-07T15:34
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher N3949796ca1a64c89ba1d3ef73e609051
41 sgo:license sg:explorer/license/
42 sgo:sdDataset patents
43 rdf:type sgo:Patent
44 N057739cbb3a540efb087ed1e3d52bf45 rdf:first N7dde1bc08f804da9a55a048227b036ef
45 rdf:rest Nb5e30d4d5ba24e07b0c3e4d57467c249
46 N1a538eda07bd402da7fd042bd06981fa schema:name GARIBAY, PATRICK, WILLIAM
47 rdf:type schema:Person
48 N3949796ca1a64c89ba1d3ef73e609051 schema:name Springer Nature - SN SciGraph project
49 rdf:type schema:Organization
50 N4a52221a3f6a453fa17a9ef0294d4150 schema:name KODRA, János, Tibor
51 rdf:type schema:Person
52 N7dde1bc08f804da9a55a048227b036ef schema:name KOFOED, JACOB
53 rdf:type schema:Person
54 Nb5e30d4d5ba24e07b0c3e4d57467c249 rdf:first N4a52221a3f6a453fa17a9ef0294d4150
55 rdf:rest Nf59b9f2503c7456e98e4121b71cefc2d
56 Nc8bf6c9e4d6042c2ae6c9caa356ca33f schema:name LINDEROTH, LARS
57 rdf:type schema:Person
58 Ne686c0905b254ca488d292ac5847bb5f rdf:first N1a538eda07bd402da7fd042bd06981fa
59 rdf:rest rdf:nil
60 Nf59b9f2503c7456e98e4121b71cefc2d rdf:first Nc8bf6c9e4d6042c2ae6c9caa356ca33f
61 rdf:rest Ne686c0905b254ca488d292ac5847bb5f
62 anzsrc-for:2464 schema:inDefinedTermSet anzsrc-for:
63 rdf:type schema:DefinedTerm
64 sg:pub.10.1007/s001250050903 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013633156
65 https://doi.org/10.1007/s001250050903
66 rdf:type schema:CreativeWork
67 https://doi.org/10.1016/0022-2836(70)90057-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021169618
68 rdf:type schema:CreativeWork
69 https://doi.org/10.1039/b312953p schema:sameAs https://app.dimensions.ai/details/publication/pub.1052479461
70 rdf:type schema:CreativeWork
71 https://www.grid.ac/institutes/grid.425956.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...